No price history available.
Key financial summary
Financials in INR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM | 2027E | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | INRm | 6,872 | 7,865 | 9,231 | 11,152 | 13,758 | 16,698 | 18,753 | N/A | N/A |
| Operating profit | INRm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | INRm | 959 | 1,359 | 1,465 | 1,793 | 2,583 | 3,386 | 3,221 | N/A | N/A |
| EPS reported | INR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | INR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | INR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | INR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | INRm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | INRm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | INRm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | INR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | INR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in INR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM | 2027E | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Value | ||||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | ||||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | ||||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | ||||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Poly Medicure Limited (PML) specializes in the production and distribution of a wide array of medical devices. Its extensive product portfolio encompasses a comprehensive range of infusion equipment, including IV cannulas, midline and arterial catheters, three-way stopcocks, various infusion sets (standard, safety winged, and measured volume), manifolds, extension lines, stylets/mandrins with luer locks, vial access spikes, central venous catheters, CVP manometers, needle-free connectors, pre-filled syringes, vascular access devices, and blood administration sets. The company also supplies diverse feeding solutions, such as nasogastric, infant, and gastro-duodenal feeding tubes, alongside umbilical catheters. Urology offerings include urine collection bags (with or without measured volume meters), Foley balloon catheters, irrigation sets, and general urine drainage catheters. For respiratory and anesthesia care, PML manufactures endotracheal tubes, tracheostomy tubes, mucus extractors, ventilator and Bain circuits, catheter mounts, spinal needles, HME filters, and laryngeal mask airways. The company also provides oncology-specific products. Oxygen and respiratory therapy devices feature endobronchial suction catheters, oxygen catheters, respiratory exercisers, nasal oxygen cannulas, oropharyngeal airways, and various oxygen masks, including variable concentration, reservoir, fixed concentration, and aerosol therapy types. Its renal care segment comprises dialyzers, blood lines, complete dialysis systems, fistula needles, hemodialysis catheters, and peritoneal dialysis and transfusion sets. Surgical drainage products include closed wound suction units, underwater seal drainage systems, high-pressure vacuum bottles, Yankauer suction sets, and thoracic drainage catheters. For phlebotomy and blood diagnostics, PML supplies blood collection tubes, safety blood collection sets, blood collection needles, erythrocyte sedimentation rate pipettes, and luer adaptors. Blood bag systems are also available. Personal protective equipment (PPE) such as face shields and polymasks, along with viral transport medium kits, form part of its offering. Further miscellaneous medical disposables encompass insulin syringes, sputum collectors, dry brushes, umbilical cord clamps, luer locks, cannula fixators, injection stoppers, luer lock injection sites, and universal caps. Established in 1995, the company is headquartered in New Delhi, India.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Poly Medicure Limited (POLYMED.NS)
No price history available.
Based on consensus from external analysts. Not Kvantra's opinion.
Poly Medicure Limited (PML) specializes in the production and distribution of a wide array of medical devices. Its extensive product portfolio encompasses a comprehensive range of infusion equipment, including IV cannulas, midline and arterial catheters, three-way stopcocks, various infusion sets (standard, safety winged, and measured volume), manifolds, extension lines, stylets/mandrins with luer locks, vial access spikes, central venous catheters, CVP manometers, needle-free connectors, pre-filled syringes, vascular access devices, and blood administration sets. The company also supplies diverse feeding solutions, such as nasogastric, infant, and gastro-duodenal feeding tubes, alongside umbilical catheters. Urology offerings include urine collection bags (with or without measured volume meters), Foley balloon catheters, irrigation sets, and general urine drainage catheters. For respiratory and anesthesia care, PML manufactures endotracheal tubes, tracheostomy tubes, mucus extractors, ventilator and Bain circuits, catheter mounts, spinal needles, HME filters, and laryngeal mask airways. The company also provides oncology-specific products. Oxygen and respiratory therapy devices feature endobronchial suction catheters, oxygen catheters, respiratory exercisers, nasal oxygen cannulas, oropharyngeal airways, and various oxygen masks, including variable concentration, reservoir, fixed concentration, and aerosol therapy types. Its renal care segment comprises dialyzers, blood lines, complete dialysis systems, fistula needles, hemodialysis catheters, and peritoneal dialysis and transfusion sets. Surgical drainage products include closed wound suction units, underwater seal drainage systems, high-pressure vacuum bottles, Yankauer suction sets, and thoracic drainage catheters. For phlebotomy and blood diagnostics, PML supplies blood collection tubes, safety blood collection sets, blood collection needles, erythrocyte sedimentation rate pipettes, and luer adaptors. Blood bag systems are also available. Personal protective equipment (PPE) such as face shields and polymasks, along with viral transport medium kits, form part of its offering. Further miscellaneous medical disposables encompass insulin syringes, sputum collectors, dry brushes, umbilical cord clamps, luer locks, cannula fixators, injection stoppers, luer lock injection sites, and universal caps. Established in 1995, the company is headquartered in New Delhi, India.
